Application No. 10/597,154 Group Art Unit: 1625

Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended): A compound of Formula (I):

wherein R¹ represents H, halogen, or a group -YZ;

Y represents a bond (i.e. is absent), C₁₋₆ alkylene or C₂₋₆ alkenylene;

Z represents an aryl or heteroaryl group each comprising 5-14 ring members, said aryl or heteroaryl being optionally substituted by one or more substituents independently selected from halogen, OH, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, CN, C₁₋₆ hydroxyalkyl, phenyl, O-(CH₂)₁₋₆-phenyl, NHSO₂R³, NHCOR³, CONR⁴R⁵, SO₂NR⁴R⁵;

 $\mathsf{R}^3,\,\mathsf{R}^4$ and R^5 independently represent H or $\mathsf{C}_{1\text{-}6}$ alkyl;

 R^2 represents H, halogen or a group $-Y^1Z^1$;

Y¹ represents a bond (i.e. is absent), C₁₋₆ alkylene, C₂₋₆ alkenylene;

 Z^1 represents a 6 membered aryl, 5 or 6 membered heteroaryl, 5 - 7 membered heterocyclyl, C_{5-7} cycloalkenyl, each of which may be optionally substituted by one or more

Substituents independently selected from
$$SO_2R^6$$
, $NHSO_2R^6$, $OCND^7R^6$, $OCND^7R^6$, $OCND^7R^6$

NR⁷R⁸, SO₂NR⁷R⁸, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, halogen, CONR⁷R⁸, NHCOR⁷, or phenyl (directly attached or attached by a C₁₋₆alkylene, CONH, C₂₋₆ alkenylene spacer and optionally substituted by one or more substituent selected from

$$-N - CH_3$$
, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, OH, halogen);

Group Art Unit: 1625

 R^6 represents H, C_{1-6} alkyl, $-(CH_2)_n$ phenyl or $-(CH_2)_n$ napthyl (where n is 0 or 1 and each of which phenyl or naphthyl may be optionally substituted by one or more substituents independently selected from C_{1-6} alkyl, C_{1-6} alkoxy, halogen, NR^7R^8 , C_{1-6} haloalkyl, C_{1-6} haloalkoxy), CN or $-(O)_p$ phenyl (where p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from halogen, C_{1-6} alkyl or C_{1-6} alkoxy)):

 R^7 and R^8 independently represents C_{1-6} alkyl, H, C_{1-6} alkylene NR^9R^{10} ;

R⁹ and R¹⁰ independently represents C₁₋₆ alkyl, H;

with the proviso R¹ and R² do not both represent H;

or a <u>pharmaceutically acceptable</u> salt[, solvate, or physiologically functional derivative] thereof.

- 2. (Original): A compound according to claim 1 wherein R¹ is YZ.
- 3. (Original): A compound according to claim 2 wherein Y is a bond or -CH = CH-.
- 4. (Original): A compound according to claim 3 wherein Y is a bond.
- 5. (Previously presented): A compound according to claim 1 wherein Z is phenyl (which may be unsubstituted or substituted once or twice by substituents independently selected from C₁₋₃ alkoxy, CN, OH, phenyl, –OCH₂ phenyl NHSO₂R³, NHCOR³, CONR⁴R⁵, SO₂NR⁴R⁵, halogen, C₁₋₃ hydroxyalkyl, C₁₋₄ alkyl) or a heteroaryl group selected from

benzofuranyl, quinolinyl, O, pyrimidinyl, thiophenyl, isoxazolyl, pyridinyl (each of which may be optionally substituted by one or two groups independently selected from C_{1-3} alkyl, C_{1-3} alkoxy, halogen.

6. (Original): A compound according to claim 5 wherein Z is phenyl (which is unsubstituted or substituted once by a substituent selected from phenyl, OCH₂ phenyl, NHSO₂CH₃, NHCOCH₃, CONH₂, CON(CH₃)₂, CI, F, OCH₃, CN, OH, CH₂OH, CH₃, C(CH₃)₃)

Group Art Unit: 1625

or a heterocyclic group selected from benzofuranyl, quinolinyl, pyridinyl, thiophenyl, benzothiophenyl, isoxazolyl, pyridinyl (each of which is substituted or is substituted once by a group selected from -OCH₃, CH₃, F).

- 7. (Original): A compound according to claim 6 wherein Z is phenyl (which is unsubstituted or substituted once by a substituent selected from phenyl, OCH₂ phenyl, NHSO₂CH₃, NHCOCH₃, CONH₂, CON(CH₃)₂, CI, F, OCH₃, CN, OH, CH₂OH, CH₃, C(CH₃)₃).
 - 8. (Original): A compound according to claim 7 wherein Z is phenyl.
 - 9. (Previously presented): A compound according to claim 1 wherein R^2 is H or Y^1Z^1 .
 - 10. (Original): A compound according to claim 9 wherein R² is Y¹Z¹.
- 11. (Original): A compound according to claim 10 wherein Y^1 is a bond or C_{1-3} alkylene.
- 12. (Withdrawn): A compound according to claim 10 wherein Z^1 is phenyl (unsubstituted or substituted by one substituent selected from NHSO₂R⁶, CONR⁷R⁸, CF₃, C₁₋₃ alkoxy, SO₂R⁶, NHCOR⁷, SO₂NR⁷R⁸, NR⁷R⁸) or a 6 membered heterocyclic group which contains one nitrogen atom (which is unsubstituted or substituted one time by a group selected from C₁₋₃ alkyl, CH₂ phenyl, SO₂R⁶, CONR⁷R⁸).
- 13. (Original): A compound according to claim 12 wherein Z¹ is a 6 membered heterocycle substituted by SO₂R⁶.
- 14. (Original): A compound according to claim 13 wherein the 6 membered heterocycle is 4-piperidyl.
 - 15. (Original): A compound according to claim 1 wherein R¹ is YZ and R² is H or Br.
- 16. (Original): A compound according to claim 1 wherein R^1 is phenyl or Br and R^2 is Y^1Z^1 .

Group Art Unit: 1625

17. (Original): A compound according to claim 1 wherein R² is YZ and R² is Y¹Z¹.

18. (Currently amended): A compound as claimed in claim 1, selected from the group consisting of:

5-phenyl-1H-indole-7-carboxamide;

5-(4-biphenylyl)-1H-indole-7-carboxamide;

5-{4-[(phenylmethyl)oxy]phenyl}-1H-indole-7-carboxamide;

5-{4-[(methylsulfonyl)amino]phenyl}-1H-indole-7-carboxamide;

5-[4-(acetylamino)phenyl]-1H-indole-7-carboxamide;

5-[3-(aminocarbonyl)phenyl]-1H-indole-7-carboxamide;

5-(4-chlorophenyl)-1H-indole-7-carboxamide;

5-[3-(acetylamino)phenyl]-1H-indole-7-carboxamide;

5-[3-(aminosulfonyl)phenyl]-1H-indole-7-carboxamide;

5-{3-[(dimethylamino)carbonyl]phenyl}-1H-indole-7-carboxamide;

5-(3-fluorophenyl)-1H-indole-7-carboxamide;

5-[3-(methyloxy)phenyl]-1H-indole-7-carboxamide;

5-(3-cyanophenyl)-1H-indole-7-carboxamide;

5-(3-hydroxyphenyl)-1H-indole-7-carboxamide;

5-(3-quinolinyl)-1H-indole-7-carboxamide;

5-(1-benzofuran-4-yl)-1H-indole-7-carboxamide;

5-(1,3-benzodioxol-5-yl)-1H-indole-7-carboxamide;

5-[(E)-2-phenylethenyl]-1H-indole-7-carboxamide;

5-(5-pyrimidinyl)-1H-indole-7-carboxamide;

5-(3-biphenylyl)-1H-indole-7-carboxamide;

5-(1-benzofuran-2-yl)-1H-indole-7-carboxamide;

5-(1-benzothien-2-yl)-1*H*-indole-7-carboxamide;

5-[3-(hydroxymethyl)phenyl]-1H-indole-7-carboxamide;

5-(2-naphthalenyl)-1H-indole-7-carboxamide;

5-(4-fluorophenyl)-1H-indole-7-carboxamide;

5-[6-(methyloxy)-3-pyridinyl]-1H-indole-7-carboxamide;

5-[4-(hydroxymethyl)phenyl]-1H-indole-7-carboxamide;

5-(3-chlorophenyl)-1H-indole-7-carboxamide;

5-(2-methylphenyl)-1H-indole-7-carboxamide;

5-{3-[(phenylmethyl)oxy]phenyl}-1H-indole-7-carboxamide;

5-(2-chlorophenyl)-1H-indole-7-carboxamide;

5-(3,5-dimethyl-4-isoxazolyl)-1H-indole-7-carboxamide;

Group Art Unit: 1625

```
5-{2-[(phenylmethyl)oxy]phenyl}-1H-indole-7-carboxamide;
```

5-(5-quinolinyl)-1H-indole-7-carboxamide;

5-(1-naphthalenyl)-1H-indole-7-carboxamide;

3-bromo-5-phenyl-1H-indole-7-carboxamide;

3-iodo-5-phenyl-1H-indole-7-carboxamide;

3,5-diphenyl-1H-indole-7-carboxamide;

3-{4-[(methylsulfonyl)amino]phenyl}-5-phenyl-1H-indole-7-carboxamide;

5-phenyl-3-(3-pyridinyl)-1*H*-indole-7-carboxamide;

3-(4-{[(2-aminoethyl)amino]carbonyl}phenyl)-5-phenyl-1*H*-indole-7-carboxamide;

3-[4-({[4-(methyloxy)-3-(4-methyl-1-piperazinyl)phenyl]amino}carbonyl)phenyl]-5-phenyl-1H-indole-7-carboxamide formate:

5-phenyl-3-[3-(trifluoromethyl)phenyl]-1H-indole-7-carboxamide;

5-bromo-3-iodo-1H-indole-7-carboxamide;

3-(1-ethyl-3-piperidinyl)-5-phenyl-1H-indole-7-carboxamide;

5-phenyl-3-(3-piperidinyl)-1H-indole-7-carboxamide;

5-phenyl-3-[1-(phenylmethyl)-3-piperidinyl]-1H-indole-7-carboxamide;

3-(1-cyclohexen-1-yl)-5-phenyl-1H-indole-7-carboxamide;

3-cyclohexyl-5-phenyl-1H-indole-7-carboxamide;

3-{1-[3-(methyloxy)phenyl]ethenyl}-5-phenyl-1H-indole-7-carboxamide;

5-phenyl-3-[1-(phenylmethyl)-1,2,3,6-tetrahydro-4-pyridinyl]-1H-indole-7-carbox-amide;

5-phenyl-3-(4-piperidinyl)-1H-indole-7-carboxamide;

3-{1-[(4-chlorophenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1H-indole-7-carboxamide;

5-phenyl-3-[1-(propylsulfonyl)-4-piperidinyl]-1H-indole-7-carboxamide;

3-(1-acetyl-4-piperidinyl)-5-phenyl-1H-indole-7-carboxamide;

3-[1-(N,N-dimethyl-β-alanyl)-4-piperidinyl]-5-phenyl-1H-indole-7-carboxamide;

3-(1-ethyl-4-piperidinyl)-5-phenyl-1H-indole-7-carboxamide formate;

3-(1-methylpyrrolidin-2-yl)-5-phenyl-1*H*-indole-7-carboxamide;

3-[1-(ethylsulfonyl)pyrrolidin-3-yl]-5-phenyl-1*H*-indole-7-carboxamide;

3-[4-(methylsulfonyl)phenyl]-5-phenyl-1*H*-indole-7-carboxamide;

3-[3-(acetylamino)phenyl]-5-phenyl-1*H*-indole-7-carboxamide;

3-[4-(ethylsulfonyl)phenyl]-5-phenyl-1*H*-indole-7-carboxamide;

3-[3-(methylsulfonyl)phenyl]-5-phenyl-1*H*-indole-7-carboxamide;

3-(hexahydro-1*H*-azepin-4-yl)-5-phenyl-1*H*-indole-7-carboxamide;

3-[1-(ethylsulfonyl)hexahydro-1H-azepin-4-yl]-5-phenyl-1H-indole-7-carbox-amide;

5-phenyl-3-[2-(4-pyridinyl)ethyl]-1*H*-indole-7-carboxamide;

3-{[1-(ethylsulfonyl)-4-piperidinylidene]methyl}-5-phenyl-1H-indole-7-carboxamide;

Group Art Unit: 1625

```
3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[4-(hydroxymethyl)phenyl]-1H-indole-7-carboxamide;
```

5-phenyl-3-(3-piperidinylmethyl)-1*H*-indole-7-carboxamide;

5-phenyl-3-[2-(4-piperidinyl)ethyl]-1*H*-indole-7-carboxamide;

3-{2-[1-(ethylsulfonyl)-4-piperidinyl]ethyl}-5-phenyl-1*H*-indole-7-carboxamide;

3-{[1-(ethylsulfonyl)-3-piperidinyl]methyl}-5-phenyl-1*H*-indole-7-carboxamide;

3-{[1-(ethylsulfonyl)-4-piperidinyl]methyl}-5-phenyl-1*H*-indole-7-carboxamide;

3-{1-[(2)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;

3-{1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;

3-{1-[(4-methylphenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;

3-{phenylsulfonyl-4-piperidinyl}-5-phenyl-1H-indole-7-carboxamide;

3-(1-{[4-(methyloxy)phenyl]sulfonyl}-4-piperidinyl)-5-phenyl-1*H*-indole-7-carboxamide;

3-[1-(ethanesulfonyl)-4-piperidinyl]-5-phenyl-1*H*-indole-7-carboxamide;

3-{1-[(2-propanesulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;

5-phenyl-3-[1-(propanesulfonyl)-1,2,3,6-tetrahydro-4-pyridinyl]-1*H*-indole-7-carboxamide;

5-phenyl-3-(1-{[4-(trifluoromethyl)phenyl]sulfonyl}-4-piperidinyl)-1*H*-indole-7-carboxamide;

3-{1-[(2,4-dichlorophenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;

3-{1-[(3,4-dichlorophenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;

3-{1-[(ethylamino)carbonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;

3-{1-[(4 -1-piperazinyl)carbonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;

5-(4-chlorophenyl)-3-[1-(propanesulfonyl)-4-piperidinyl]-1*H*-indole-7-carboxamide;

3-{1-[(4-fluorophenyl)sulfonyl]-4-piperidinyl}-5-(4-chlorophenyl)-1*H*-indole-7-carboxamide;

5-{4-[(methylsulfonyl)amino]phenyl}-3-[1-(phenylmethyl)-1,2,3,6-tetrahydro-4-pyridinyl]-1*H*-indole-7-carboxamide;

5-{4-[(methylsulfonyl)amino]phenyl}-3-(4-piperidinyl)-1*H*-indole-7-carboxamide;

5-bromo-3-[1-(ethanesulfonyl)-4-piperidinyl]-1*H*-indole-7-carboxamide;

3-[1-(ethanesulfonyl)-4-piperidinyl]-5-{4-[(methylsulfonyl)amino]phenyl}-1*H*-indole-7-carboxamide;

3-[1-(ethanesulfonyl)-4-piperidinyl]-5-(3-methylphenyl)-1H-indole-7-carboxamide;

3-[1-(ethylsulfonyl)-4-piperidinyl]-5-(2-thienyl)-1*H*-indole-7-carboxamide;

3-[1-(ethylsulfonyl)-4-piperidinyl]-5-(3-thienyl)-1*H*-indole-7-carboxamide;

3-[4-(methylsulfonyl)phenyl]-5-phenyl-1H-indole-7-carboxamide;

3-{4-[(dimethylamino)sulfonyl]phenyl}-5-phenyl-1H-indole-7-carboxamide;

3-{3-[(methylsulfonyl)amino]phenyl}-5-phenyl-1H-indole-7-carboxamide;

3-[1-(ethylsulfonyl)-4-piperidinyl]-5-{3-[(methylsulfonyl)amino]phenyl}-1*H*-indole -7-carboxamide;

5-[4-(acetylamino)phenyl]-3-[1-(ethylsulfonyl)-4-piperidinyl]-1*H*-indole-7-carboxamide;

Application No. 10/597,154 Group Art Unit: 1625

carboxamide;

```
5-{4-[(dimethylamino)sulfonyl]phenyl}-3-[1-(ethylsulfonyl)-4-piperidinyl]-1H-indole-7-
```

- 5-[3-(acetylamino)phenyl]-3-[1-(ethylsulfonyl)-4-piperidinyl]-1*H*-indole-7-carbox-amide;
- 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-(1*H*-pyrazol-4-yl)-1*H*-indole-7-carboxamide;
- 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[3-(hydroxymethyl)phenyl]-1*H*-indole-7-carboxamide;
- 5-(2,4-difluorophenyl)-3-[1-(ethylsulfonyl)-4-piperidinyl]-1*H*-indole-7-carboxamide;
- 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[4-(methyloxy)phenyl]-1*H*-indole-7-carboxamide;
- 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-(4-fluoro-2-methylphenyl)-1*H*-indole-7-carboxamide;
- 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-(4-fluorophenyl)-1*H*-indole-7-carboxamide;
- 5-(4-biphenylyl)-3-[1-(ethylsulfonyl)-4-piperidinyl]-1*H*-indole-7-carboxamide;
- 5-[4-(1,1-dimethylethyl)phenyl]-3-[1-(ethylsulfonyl)-4-piperidinyl]-1*H*-indole-7-carboxamide;
- 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-(4-methylphenyl)-1*H*-indole-7-carboxamide;
- 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-(4-pyridinyl)-1*H*-indole-7-carboxamide;
- 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-(6-fluoro-3-pyridinyl)-1*H*-indole-7-carboxamide;
- 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-(6-methyl-3-pyridinyl)-1*H*-indole-7-carboxamide;
- 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-(4-methyl-3-pyridinyl)-1*H*-indole-7-carboxamide;
- 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[6-(methyloxy)-3-pyridinyl]-1*H*-indole-7-carboxamide;
- 5-phenyl-3-(*N*-acetyl-3-piperidinylmethyl)-1*H*-indole-7-carboxamide;
- 5-[3-(ethyloxy)phenyl]-3-[1-(ethylsulfonyl)-4-piperidinyl]-1*H*-indole-7-carboxamide;
- 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-(2-fluorophenyl)-1*H*-indole-7-carboxamide;
- 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[3-(trifluoromethyl)phenyl]-1*H*-indole-7-carboxamide;
- 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[4-(trifluoromethyl)phenyl]-1*H*-indole-7-carboxamide;
- 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-(3-fluorophenyl)-1*H*-indole-7-carboxamide;
- 5-(3,5-dichlorophenyl)-3-[1-(ethylsulfonyl)-4-piperidinyl]-1*H*-indole-7-carboxamide;
- 5-(3,4-difluorophenyl)-3-[1-(ethylsulfonyl)-4-piperidinyl]-1*H*-indole-7-carboxamide;
- 3-bromo-5-{3-[(dimethylamino)carbonyl]phenyl}-1*H*-indole-7-carboxamide;
- 5-[2,6-bis(methyloxy)phenyl]-3-bromo-1*H*-indole-7-carboxamide;
- 3-bromo-5-(4-fluoro-2-methylphenyl)-1*H*-indole-7-carboxamide;
- 3-bromo-5-[5-fluoro-2-(methyloxy)phenyl]-1*H*-indole-7-carboxamide;
- 3-bromo-5-(3-quinolinyl)-1*H*-indole-7-carboxamide trifluoroacetate;
- 3-bromo-5-(5-quinolinyl)-1*H*-indole-7-carboxamide trifluoroacetate;
- 5-[2,5-bis(methyloxy)phenyl]-3-bromo-1*H*-indole-7-carboxamide;
- 3-bromo-5-(2-fluorophenyl)-1*H*-indole-7-carboxamide;
- 5-[2,4-bis(methyloxy)phenyl]-3-bromo-1*H*-indole-7-carboxamide;
- 3-bromo-5-[2-(methyloxy)-3-pyridinyl]-1*H*-indole-7-carboxamide trifluoroacetate;
- 3-bromo-5-[2,3,4-tris(methyloxy)phenyl]-1*H*-indole-7-carboxamide;

Group Art Unit: 1625

- 3-{1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;
- 3-(1-{[5-bromo-2-(methyloxy)phenyl]sulfonyl}-4-piperidinyl)-5-phenyl-1*H*-indole-7-carboxamide;
- 3-{1-[(5-fluoro-2-methylphenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;
- 3-{1-[(3-fluorophenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;
- 5-phenyl-3-(1-{[2,4,6-tris(1-methylethyl)phenyl]sulfonyl}-4-piperidinyl)-1*H*-indole-7-carboxamide;
- 3-(1-{[4-(1,1-dimethylpropyl)phenyl]sulfonyl}-4-piperidinyl)-5-phenyl-1*H*-indole-7-carboxamide;
- 3-{1-[(2-methylphenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;
- 3-{1-[(2-iodophenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;
- 3-{1-[(4-pentylphenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;
- 5-phenyl-3-{1-[(4-propylphenyl)sulfonyl]-4-piperidinyl}-1*H*-indole-7-carboxamide;
- 3-{1-[(2,4-difluorophenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;
- 3-{1-[(2,5-dimethylphenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;
- 3-{1-[(4-ethylphenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;
- 3-{1-[(3-methylphenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;
- 3-{1-[(4-{[2-(methyloxy)phenyl]oxy}phenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;
- 3-{1-[(4-{[4-(methyloxy)phenyl]oxy}phenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;
- 3-[1-({3-[(4-fluorophenyl)oxy]phenyl}sulfonyl)-4-piperidinyl]-5-phenyl-1*H*-indole-7-carboxamide;
- 3-{1-[(3-{[2-(methyloxy)phenyl]oxy}phenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;
- 3-[1-({4-[(4-chlorophenyl)oxy]phenyl}sulfonyl)-4-piperidinyl]-5-phenyl-1*H*-indole-7-carboxamide;
- 3-{1-[(3-{[4-(methyloxy)phenyl]oxy}phenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;
- 5-phenyl-3-(1-{[3-(phenyloxy)phenyl]sulfonyl}-4-piperidinyl)-1*H*-indole-7-carboxamide;
- 3-[1-({3-[(4-chlorophenyl)oxy]phenyl}sulfonyl)-4-piperidinyl]-5-phenyl-1*H*-indole-7-carboxamide;
- 3-[1-({4-[(2-methylphenyl)oxy]phenyl}sulfonyl)-4-piperidinyl]-5-phenyl-1*H*-indole-7-carboxamide;
- 3-{1-[(4'-chloro-4-biphenylyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;

Group Art Unit: 1625

3-[1-({3-[(2-methylphenyl)oxy]phenyl}sulfonyl)-4-piperidinyl]-5-phenyl-1*H*-indole-7-carboxamide;

3-[1-({3-[(2-chlorophenyl)oxy]phenyl}sulfonyl)-4-piperidinyl]-5-phenyl-1*H*-indole-7-carboxamide;

3-{1-[(5-chloro-1-naphthalenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;

3-(1-{[4'-(methyloxy)-3-biphenylyl]sulfonyl}-4-piperidinyl)-5-phenyl-1*H*-indole-7-carboxamide;

3-[1-(3-biphenylylsulfonyl)-4-piperidinyl]-5-phenyl-1*H*-indole-7-carboxamide;

3-(1-{[(4-fluorophenyl)methyl]sulfonyl}-4-piperidinyl)-5-phenyl-1*H*-indole-7-carboxamide;

3-{1-[(5-chloro-2-naphthalenyl)sulfonyl]-4-piperidinyl}-5-phenyl-1*H*-indole-7-carboxamide;

3-(1-{[4'-(methyloxy)-4-biphenylyl]sulfonyl}-4-piperidinyl)-5-phenyl-1*H*-indole-7-carboxamide;

5-(2-fluorophenyl)-1*H*-indole-7-carboxamide;

5-(3-{[(2,2-dimethylpropyl)amino]carbonyl}phenyl)-1*H*-indole-7-carboxamide;

5-(3-{[(1-methylethyl)amino]carbonyl}phenyl)-1*H*-indole-7-carboxamide;

5-(4-{[(2,2-dimethylpropyl)amino]carbonyl}phenyl)-1*H*-indole-7-carboxamide;

5-{4-[(propylamino)carbonyl]phenyl}-1*H*-indole-7-carboxamide;

5-(4-{[(1-methylethyl)amino]carbonyl}phenyl)-1*H*-indole-7-carboxamide;

5-{4-[(diethylamino)carbonyl]phenyl}-1*H*-indole-7-carboxamide;

3-[1-(methylsulfonyl)-1,2,3,6-tetrahydro-4-pyridinyl]-5-phenyl-1*H*-indole-7-carboxamide;

3-(3-oxocyclopentyl)-5-phenyl-1*H*-indole-7-carboxamide;

5-phenyl-3-{3-[(phenylmethyl)amino]cyclopentyl}-1*H*-indole-7-carboxamide;

3-(3-aminocyclopentyl)-5-phenyl-1*H*-indole-7-carboxamide;

3-{3-[(ethylsulfonyl)amino]cyclopentyl}-5-phenyl-1*H*-indole-7-carboxamide;

5-bromo-3-[1-(propylsulfonyl)-4-piperidinyl]-1*H*-indole-7-carboxamide;

5-bromo-3-(3-pyridinyl)-1H-indole-7-carboxamide;

5-bromo-3-[1-(methylsulfonyl)-1,2,3,6-tetrahydro-4-pyridinyl]-1*H*-indole-7-carboxamide;

3-[(4-hydroxyphenyl)methyl]-5-phenyl-1H-indole-7-carboxamide;

5-bromo-1H-indole-7-carboxamide;

5-(4-chlorophenyl)1H-indole-7-carboxamide;

5-bromo-3(4-piperidinyl)1H-indole-7-carboxamide;

or a <u>pharmaceutically acceptable</u> salt[, solvate, or physiologically functional derivative] thereof.

19. (Currently amended): A pharmaceutical composition, comprising a compound as claimed in claim 1, or a <u>pharmaceutically acceptable</u> salt[, solvate, or a physiologically

Application No. 10/597,154 Group Art Unit: 1625

functional derivative] thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

Claims 20-22 (Cancelled)

- 23. (Withdrawn): A method of treating a disorder in a mammal, said disorder being mediated by inappropriate kinase activity, comprising administering to said mammal a compound as claimed in claim 1, or a salt, solvate, or a physiologically functional derivative thereof.
- 24. (Withdrawn): A method according to claim 23 wherein the inappropriate kinase activity is inappropriate IKK2 activity.
- 25. (Withdrawn): A method according to claim 24 wherein the disorder mediated by inappropriate IKK2 activity is inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease); osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultraviolet radiation (UV)-induced skin damage; autoimmune diseases including systemic lupus eythematosus, multiple sclerosis, psoriatic arthritis, alkylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restonosis, diabetes, glomerulonephritis, cancer, including Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including acquired immune deficiency syndrome (AIDS), adult respiratory distress syndrome, and Ataxia Telangiestasia, comprising administering a therapeutically effective amount to a mammal of a compound of formula (I), or a salt, solvate or pharmaceutically functional derivative thereof.

Claims 26-38 (Cancelled)